(Reuters) - The Marlborough, Massachusetts-based drug company said net profit was $6.1 million, or 5 cents per diluted share, compared with $11.0 million, or 10 cents per diluted share, a year ago.
Revenue rose to $278.1 million from $264.4 million. Analysts, on average, expected revenue of $327.2 million.
Read more at Reuters.com Market News
Revenue rose to $278.1 million from $264.4 million. Analysts, on average, expected revenue of $327.2 million.
Read more at Reuters.com Market News
No comments:
Post a Comment